ClinicalTrials.gg
RecruitingNCT07454343Updated Mar 6, 2026

ECD-Score: a Study on Erdheim-Chester Disease

An observational study in Erdheim-Chester Disease (ECD), sponsored by Meyer Children's Hospital IRCCS. Recruiting at 7 sites in 4 countries. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Meyer Children's Hospital IRCCS · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Erdheim-Chester Disease with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Erdheim-Chester Disease · United States.

Started
2024
the only one that year
Observational
8 of 15
5 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Meyer Children's Hospital IRCCS

Among the 15 studies in Erdheim-Chester Disease with a site in United States, this one is the only one that started in 2024, is one of 8 observational ones, and was the 15th registered.

Erdheim-Chester Disease

22 studies on the registry are indexed under Erdheim-Chester Disease; 11 are open to participants now.

Browse Erdheim-Chester Disease studies →

Open to participants now

7 of the 15 studies in Erdheim-Chester Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Erdheim-Chester Disease studies recruiting now, 8 (73%) set no upper age limit and 1 (9%) stops at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 7 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Erdheim-Chester Disease with a site in United States, or all of them as a file.
02

Study summary

Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis that primarily affects adults but may also occur in pediatric patients. It is characterized by the accumulation of foamy histiocytes with a distinctive immunophenotype in multiple anatomical sites, most commonly the long bones, retroperitoneal and perirenal tissues, the heart, the central nervous system, and the pituitary gland. The disease shows marked clinical heterogeneity, ranging from localized and asymptomatic forms to severe manifestations with multiorgan involvement. From a pathogenetic perspective, ECD is mainly driven by gain-of-function mutations affecting the MAPK and PI3K-AKT pathways, particularly the BRAFV600E mutation, leading to aberrant activation of the MAPK and mTOR signaling pathways. The release of pro-inflammatory cytokines and chemokines plays a key role in systemic inflammation and tissue damage, resulting in significant complications and disability depending on the organs involved.

Despite the significant efforts of international research in recent years, particularly given the extreme rarity of the disease (incidence below 5 cases per 10,000,000 adults per year), substantial knowledge gaps remain, especially with regard to the prediction of long-term outcomes, both in terms of survival and disability. Although some prognostic factors associated with survival have already been identified (such as central nervous system involvement), to date only limited-scale studies have systematically evaluated the prognosis of patients with ECD, focusing in particular on factors influencing organ-specific complications. Moreover, in clinical practice, several aspects that significantly affect patients' quality of life tend to be underestimated, partly due to the time required to perform comprehensive assessments using detailed questionnaires designed to quantify disease-related consequences, such as chronic disability, depression, and cognitive impairment. Nevertheless, there is a growing need for and interest in these parameters, commonly referred to as patient-reported outcomes. In light of these considerations, the development and implementation of a comprehensive prognostic score aimed at predicting survival and long-term disease outcomes could improve the overall assessment of patients and provide more accurate and clinically meaningful prognostic information.

03

Conditions studied

  • Erdheim-Chester Disease (ECD)
04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with ECD will be recruited and will attend outpatient visits at the study coordination center at the Meyer IRCCS University Hospital (Florence) and other participating centers. The patients to be enrolled will be "prevalent" and "incident" patients during the 5-year study period. Patients undergoing follow-up at their respective centers will be involved in the study, as well as those who receive a new diagnosis of ECD during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed by the patient or, for minors, by a parent or legal guardian
  • confirmed diagnosis of ECD according to the latest international guidelines (Goyal G, Blood 2020)
  • availability of clinical, molecular, treatment and response to therapy data
  • a minimum follow-up period of one year.

Exclusion criteria

Exclusion Criteria:

  • lack of diagnostic or follow-up data
  • refusal or inability to sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with Erdheim-Chester disease (ECD)

    Patients with ECD will be recruited and will attend outpatient visits at the study coordination center at the Meyer IRCCS University Hospital (Florence) and other participating centers. The patients to be enrolled will be "prevalent" and "incident" patients during the 5-year study period. Patients undergoing follow-up at their respective centers will be involved in the study, as well as those who receive a new diagnosis of ECD during the study period. Clinical data will be collected from all patients included, focusing primarily on organ involvement and response to treatment. They will also be asked to complete questionnaires on quality of life and other specific outcomes. Epidemiological data will also be considered, in particular the geographical origin of patients, and survival rates will also be evaluated.

06

What researchers measure

Primary outcomes

  1. Overall survival

    The time from the patient's enrollment in the study until death or the last available follow-up

    Time frame: 5 years

  2. Association between belonging to a clinical cluster and survival

    Clinical cluster of ECD

    Time frame: 5 years

  3. Association between organ damage and survival

    organ damage related to the disease (e.g., chronic kidney failure)

    Time frame: 5 years

  4. Association between the treatment used (relative to the historical period) and survival

    treatment received

    Time frame: 5 years

  5. Association between response to treatment and survival

    complete response rate, partial response, stable disease, progression

    Time frame: 5 years

  6. Association between treatment toxicity and survival

    incidence and severity of adverse events (classified according to CTCAE v6.0)

    Time frame: 5 years

  7. Association between comorbidities and survival

    presence of malignant tumors and other chronic diseases

    Time frame: 5 years

  8. Association between geographical origin and survival

    geographical origin

    Time frame: at enrollment

Secondary outcomes

  1. Incidence of comorbidities secondary to the disease or treatment (e.g., secondary malignancies)

    To assess the incidence of organ damage related to the disease or comorbidities secondary to the disease or the treatment received

    Time frame: 5 years

  2. Association between disease and quality of life

    Assessment of the impact on quality of life following disease diagnosis and in response to treatment, using validated questionnaires

    Time frame: 5 years

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jun 2028, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Dec 23, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454343
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Augusto Vaglio (Principal Investigator, Meyer Children's Hospital IRCCS) — Principal investigator
First posted
Mar 6, 2026
Start date
Dec 23, 2024
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 6, 2026

Study contacts

Augusto Vaglio, Medical Doctor
Contact
augusto.vaglio@meyer.it
055 5662905
Augusto Vaglio, Medical Doctor
principal investigator · Meyer Children's Hospital IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion